JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB192871

重组Anti-MIP-3 beta/CCL19抗体[EPR7043(2)]

Anti-MIP-3 beta/CCL19 antibody [EPR7043(2)]

Be the first to review this product! Submit a review

|

(3 Publications)

Rabbit Recombinant Monoclonal MIP-3 beta/CCL19 antibody. Suitable for WB and reacts with Recombinant full length protein - Human samples. Cited in 3 publications.

查看别名

ELC, MIP3B, SCYA19, CCL19, C-C motif chemokine 19, Beta-chemokine exodus-3, CK beta-11, Epstein-Barr virus-induced molecule 1 ligand chemokine, Macrophage inflammatory protein 3 beta, Small-inducible cytokine A19, EBI1 ligand chemokine, MIP-3-beta

1 Images
Western blot - Anti-MIP-3 beta/CCL19 antibody [EPR7043(2)] (AB192871)
  • WB

Supplier Data

Western blot - Anti-MIP-3 beta/CCL19 antibody [EPR7043(2)] (AB192871)

All lanes:

Western blot - Anti-MIP-3 beta/CCL19 antibody [EPR7043(2)] (ab192871) at 1/2000 dilution

All lanes:

MIP-3 beta/CCL19 recombinant protein at 10 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

Predicted band size: 11 kDa

Observed band size: 11 kDa

false

不同偶联物与剂型 (1)

  • Carrier free

    Anti-MIP-3 beta/CCL19 antibody [EPR7043(2)] - BSA and Azide free

关键信息

宿主种属

Rabbit

克隆

Monoclonal

克隆号

EPR7043(2)

亚型

IgG

不含载体蛋白

No

应用

WB

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

反应性数据

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Recombinant full length protein - Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/2000", "WB-species-notes": "<p></p>" } } }

产品详情

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

性能和储存信息

形式
Liquid
纯化工艺
Affinity purification Protein A
存储溶液
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
运输条件
Conditional Ambient
推荐的短期储存时间
1-2 weeks
推荐的短期储存条件
+4°C
推荐的长期储存条件
-20°C
分装信息
Upon delivery aliquot
储存信息
Avoid freeze / thaw cycle

补充信息

This supplementary information is collated from multiple sources and compiled automatically.

MIP-3 beta also known as CCL19 is a chemokine involved in immune responses. It weighs around 11 kDa and is encoded by the CCL19 gene. MIP-3 beta does its function by binding to its receptor CCR7 which is common in lymph nodes and other lymphoid tissues. It recruits and directs the migration of immune cells especially T cells and dendritic cells navigating them towards lymphoid tissues. This makes MIP-3 beta integral in initiating and modulating immune responses.
Biological function summary

MIP-3 beta helps direct cell trafficking within the lymphoid organs. It is not part of a complex but its interaction with the CCR7 receptor is essential for its biological activity. This binding plays a role in the development of secondary lymphoid organs and immune surveillance. Furthermore MIP-3 beta supports the homing of immune cells to appropriate locations impacting both innate and adaptive immune responses.

Pathways

MIP-3 beta is associated with the chemokine signaling pathway and the immune system pathway. Through these pathways it interacts with proteins like CCR7 and other chemokines that regulate leukocyte migration and activation. These pathways ensure local and systemic immune responses are efficiently orchestrated impacting inflammation and immune regulation.

MIP-3 beta has connections to autoimmune diseases like rheumatoid arthritis and cancer. Its deregulation can result in abnormal immune surveillance contributing to the pathology of these conditions. MIP-3 beta regulates immune cell infiltration and any imbalance may also link it to other inflammatory disorders. Relations to proteins such as CCR7 in these conditions emphasize its role in disease pathogenesis and highlight its potential as a therapeutic target.

产品实验方案

For this product, it's our understanding that no specific protocols are required. You can visit:

靶点信息

May play a role not only in inflammatory and immunological responses but also in normal lymphocyte recirculation and homing. May play an important role in trafficking of T-cells in thymus, and T-cell and B-cell migration to secondary lymphoid organs. Binds to chemokine receptor CCR7. Recombinant CCL19 shows potent chemotactic activity for T-cells and B-cells but not for granulocytes and monocytes. Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4.
See full target information CCL19

文献 (3)

Recent publications for all applications. Explore the full list and refine your search

Journal of inflammation research 18:13711-13726 PubMed41064490

2025

Comprehensive Analysis and Experimental Validation of Immune-Related Biomarkers and Immune Microenvironment in Diabetic Nephropathy.

Applications

Unspecified application

Species

Unspecified reactive species

Weini Zhou,Ziyang Zeng,Xunjia Li,Mei Yang

Frontiers in genetics 13:830437 PubMed35222545

2022

Identification of CCL19 as a Novel Immune-Related Biomarker in Diabetic Nephropathy.

Applications

Unspecified application

Species

Unspecified reactive species

Hanzhi Chen,Zhijian Zhang,Leting Zhou,Ting Cai,Bin Liu,Liang Wang,Junwei Yang

Cell death & disease 12:191 PubMed33602903

2021

c-MYC-induced long noncoding RNA MEG3 aggravates kidney ischemia-reperfusion injury through activating mitophagy by upregulation of RTKN to trigger the Wnt/β-catenin pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Dajun Liu,Ying Liu,Xiaotong Zheng,Naiquan Liu
View all publications

Abcam Product Promise

我们致力于为您的研究提供高质量的试剂,为您科研的每一步提供支持。若我们的产品未能达到预期性能,我们向您提供 Abcam Product Promise 保障。
详情请参阅我们的条款与条件。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com